Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals

CONCLUSIONS: Our data suggest limited survival benefits from METi, ICIs, and chemotherapy for METex14 lung cancer patients. While not statistically significant, these findings underscore the need for larger trials for validation. Identifying effective treatments for this challenging lung cancer subtype remains a priority.PMID:37897706 | DOI:10.1080/0284186X.2023.2269310

Source: Acta Oncologica - October 28, 2023 Category: Cancer & Oncology Authors: Marcus Skribek Hans Brunnstr öm Gudrun Oskarsdottir Mikel Portu Griv é Ozan Aricak Maria Planck Kenbugul Jatta Homeyra Naserhojati Felix Haglund de Flon Simon Ekman Source Type: research